{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:31:54Z","timestamp":1787758314158,"version":"build-2784847793"},"reference-count":97,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Optic neuritis, an optic nerve inflammatory disease presenting with acute unilateral or bilateral visual loss, is one of the core symptoms of neuromyelitis optica spectrum disorder (NMOSD). The diagnosis of NMOSD-related optic neuritis is challenging, and it is mainly based on clinical presentation, optical coherence tomography, magnetic resonance imaging scans, and the status of serum aquaporin-4 antibodies. In the pathogenesis, aquaporin-4 antibodies target astrocytes in the optic nerves, spinal cord and some specific regions of the brain eliciting a devastating autoimmune response. Current pharmacological interventions are directed against various steps within the immunological response, notably the terminal complement system, B-cells, and the pro-inflammatory cytokine Interleukin 6 (IL6). Conventional maintenance therapies were off-label uses of the unspecific immunosuppressants azathioprine and mycophenolate mofetil as well as the CD20 specific antibody rituximab and the IL6 receptor specific antibody tocilizumab. Recently, four phase III clinical trials demonstrated the safety and efficacy of the three novel biologics eculizumab, inebilizumab, and satralizumab. These monoclonal antibodies are directed against the complement system, CD19 B-cells and the IL6 receptor, respectively. All three have been approved for NMOSD in the US and several other countries worldwide and thus provide convincing treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/2211-5056.355617","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T04:16:46Z","timestamp":1662351406000},"page":"249-263","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["What's new in neuromyelitis optica spectrum disorder treatment?"],"prefix":"10.4103","volume":"12","author":[{"given":"Yi-Ching","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Lun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20240830","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jamaophthalmol.2017.5470","article-title":"Incidence and causes of overdiagnosis of optic neuritis","volume":"136","author":"Stunkel","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R2-2-20240830","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front Neurol"},{"key":"R3-2-20240830","doi-asserted-by":"crossref","first-page":"e2265","DOI":"10.1212\/WNL.0000000000006645","article-title":"Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark","volume":"91","author":"Papp","year":"2018","journal-title":"Neurology"},{"key":"R4-2-20240830","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1136\/jnnp-2016-314839","article-title":"Incidence and prevalence of NMOSD in Australia and New Zealand","volume":"88","author":"Bukhari","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R5-2-20240830","doi-asserted-by":"crossref","first-page":"102425","DOI":"10.1016\/j.msard.2020.102425","article-title":"Epidemiology and comorbidities of adult multiple sclerosis and neuromyelitis optica in Taiwan, 2001-2015","volume":"45","author":"Fang","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R6-2-20240830","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"key":"R7-2-20240830","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1001\/archneurol.2012.249","article-title":"Effects of age and sex on aquaporin-4 autoimmunity","volume":"69","author":"Quek","year":"2012","journal-title":"Arch Neurol"},{"key":"R8-2-20240830","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1212\/NXI.0000000000000339","article-title":"Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study","volume":"4","author":"Bove","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R9-2-20240830","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: A decade later","volume":"1366","author":"Pittock","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"R10-2-20240830","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1177\/1352458517735191","article-title":"Epidemiology of NMOSD in catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates","volume":"24","author":"Sep\u00falveda","year":"2018","journal-title":"Mult Scler"},{"key":"R11-2-20240830","doi-asserted-by":"crossref","first-page":"103030","DOI":"10.1016\/j.msard.2021.103030","article-title":"The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis","volume":"53","author":"Li","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"R12-2-20240830","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1212\/NXI.0000000000000269","article-title":"Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder","volume":"3","author":"Kessler","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R13-2-20240830","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.msard.2016.11.008","article-title":"Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders","volume":"11","author":"Schmidt","year":"2017","journal-title":"Mult Scler Relat Disord"},{"key":"R14-2-20240830","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"key":"R15-2-20240830","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"key":"R16-2-20240830","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R17-2-20240830","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3389\/fneur.2019.01028","article-title":"AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD","volume":"10","author":"Prain","year":"2019","journal-title":"Front Neurol"},{"key":"R18-2-20240830","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"R19-2-20240830","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/ceo.13863","article-title":"Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review","volume":"49","author":"Sharma","year":"2021","journal-title":"Clin Exp Ophthalmol"},{"key":"R20-2-20240830","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40265-018-1039-7","article-title":"Pharmacotherapy for neuromyelitis optica spectrum disorders: Current management and future options","volume":"79","author":"Collongues","year":"2019","journal-title":"Drugs"},{"key":"R21-2-20240830","doi-asserted-by":"crossref","first-page":"14603","DOI":"10.1038\/s41598-021-93976-1","article-title":"Clinical characteristics of optic neuritis phenotypes in a 3-year follow-up Chinese cohort","volume":"11","author":"Feng","year":"2021","journal-title":"Sci Rep"},{"key":"R22-2-20240830","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00415-020-10352-1","article-title":"The changing landscape of optic neuritis: A narrative review","volume":"269","author":"De Lott","year":"2022","journal-title":"J Neurol"},{"key":"R23-2-20240830","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/1352458514567216","article-title":"Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography","volume":"21","author":"Bennett","year":"2015","journal-title":"Mult Scler"},{"key":"R24-2-20240830","first-page":"2055217318791196","article-title":"Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis","volume":"4","author":"Srikajon","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"R25-2-20240830","doi-asserted-by":"crossref","first-page":"e02125","DOI":"10.1002\/brb3.2125","article-title":"Optical coherence tomography angiography helps distinguish multiple sclerosis from AQP4-IgG-seropositive neuromyelitis optica spectrum disorder","volume":"11","author":"Liu","year":"2021","journal-title":"Brain Behav"},{"key":"R26-2-20240830","doi-asserted-by":"crossref","first-page":"10697","DOI":"10.1038\/s41598-021-90036-6","article-title":"Differentiation between multiple sclerosis and neuromyelitis optica spectrum disorder using optical coherence tomography angiography","volume":"11","author":"Rogaczewska","year":"2021","journal-title":"Sci Rep"},{"key":"R27-2-20240830","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2377-10-45","article-title":"Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis","volume":"10","author":"Nakajima","year":"2010","journal-title":"BMC Neurol"},{"key":"R28-2-20240830","doi-asserted-by":"crossref","first-page":"e1068","DOI":"10.1212\/NXI.0000000000001068","article-title":"Retinal optical coherence tomography in neuromyelitis optica","volume":"8","author":"Oertel","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R29-2-20240830","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/bjophthalmol-2018-312231","article-title":"Peripapillary and parafoveal vascular network assessment by optical coherence tomography angiography in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorders","volume":"103","author":"Huang","year":"2019","journal-title":"Br J Ophthalmol"},{"key":"R30-2-20240830","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/WNO.0b013e318254c62d","article-title":"Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis","volume":"32","author":"Khanna","year":"2012","journal-title":"J Neuroophthalmol"},{"key":"R31-2-20240830","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/brain\/awy010","article-title":"Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica","volume":"141","author":"Wilson","year":"2018","journal-title":"Brain"},{"key":"R32-2-20240830","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/acn3.418","article-title":"CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder","volume":"4","author":"Kowarik","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"R33-2-20240830","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXI.0000000000000104","article-title":"B lymphocytes in neuromyelitis optica","volume":"2","author":"Bennett","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R34-2-20240830","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s40478-019-0766-7","article-title":"Complement-independent bystander injury in AQP4-IgG seropositive neuromyelitis optica produced by antibody-dependent cellular cytotoxicity","volume":"7","author":"Duan","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"R35-2-20240830","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R36-2-20240830","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cca.2017.03.006","article-title":"Interleukin-6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica","volume":"469","author":"Uzawa","year":"2017","journal-title":"Clin Chim Acta Int J Clin Chem"},{"key":"R37-2-20240830","doi-asserted-by":"crossref","first-page":"e1076","DOI":"10.1212\/NXI.0000000000001076","article-title":"New BBB model reveals that IL-6 blockade suppressed the BBB disorder, preventing onset of NMOSD","volume":"8","author":"Takeshita","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R38-2-20240830","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"R39-2-20240830","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/brain\/awaa102","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: An immunopathological study","volume":"143","author":"Takai","year":"2020","journal-title":"Brain"},{"key":"R40-2-20240830","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"R41-2-20240830","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11940-015-0378-x","article-title":"Acute and chronic management of neuromyelitis optica spectrum disorder","volume":"17","author":"Sherman","year":"2015","journal-title":"Curr Treat Options Neurol"},{"key":"R42-2-20240830","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1212\/NXI.0000000000000504","article-title":"Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions","volume":"5","author":"Kleiter","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R43-2-20240830","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R44-2-20240830","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R45-2-20240830","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00417-010-1344-7","article-title":"Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica","volume":"248","author":"Nakamura","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R46-2-20240830","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult Scler"},{"key":"R47-2-20240830","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1177\/1352458511429012","article-title":"Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response","volume":"18","author":"Seifert","year":"2012","journal-title":"Mult Scler"},{"key":"R48-2-20240830","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1007\/s00415-020-10257-z","article-title":"Therapeutic plasma exchange vs. conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): A systematic review and meta-analysis","volume":"268","author":"Siritho","year":"2021","journal-title":"J Neurol"},{"key":"R49-2-20240830","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00415-016-8073-8","article-title":"Plasma exchange response in 34 patients with severe optic neuritis","volume":"263","author":"Deschamps","year":"2016","journal-title":"J Neurol"},{"key":"R50-2-20240830","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","article-title":"Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica","volume":"130","author":"Merle","year":"2012","journal-title":"Arch Ophthalmol"},{"key":"R51-2-20240830","doi-asserted-by":"crossref","first-page":"E5021","DOI":"10.3390\/ijms21145021","article-title":"Differential effects of MS therapeutics on B cells-implications for their use and failure in AQP4-positive NMOSD patients","volume":"21","author":"Traub","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R52-2-20240830","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1177\/1352458513495938","article-title":"Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: Experience in 10 patients","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler"},{"key":"R53-2-20240830","doi-asserted-by":"crossref","first-page":"102325","DOI":"10.1016\/j.msard.2020.102325","article-title":"Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD)","volume":"44","author":"Li","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R54-2-20240830","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/WCO.0000000000000813","article-title":"Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4-IgG- and MOG-IgG-associated diseases","volume":"33","author":"Mader","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"R55-2-20240830","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: A retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"key":"R56-2-20240830","doi-asserted-by":"crossref","first-page":"102750","DOI":"10.1016\/j.msard.2021.102750","article-title":"Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy","volume":"49","author":"Takai","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"R58-2-20240830","doi-asserted-by":"crossref","first-page":"8638","DOI":"10.3390\/ijms22168638","article-title":"Treatment of neuromyelitis Optica Spectrum Disorders","volume":"22","author":"Chan","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R59-2-20240830","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder","volume":"18","author":"Kim","year":"2012","journal-title":"Mult Scler"},{"key":"R60-2-20240830","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"R61-2-20240830","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"key":"R62-2-20240830","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","article-title":"New therapies for neuromyelitis optica spectrum disorder","volume":"20","author":"Levy","year":"2021","journal-title":"Lancet Neurol"},{"key":"R63-2-20240830","doi-asserted-by":"crossref","first-page":"102484","DOI":"10.1016\/j.msard.2020.102484","article-title":"Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: A meta-analysis of real-world studies","volume":"46","author":"Luo","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"R64-2-20240830","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1177\/1352458517730131","article-title":"Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders","volume":"24","author":"Mealy","year":"2018","journal-title":"Mult Scler"},{"key":"R65-2-20240830","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jns.2017.12.034","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder","volume":"385","author":"Yang","year":"2018","journal-title":"J Neurol Sci"},{"key":"R66-2-20240830","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: A randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J Neurol"},{"key":"R67-2-20240830","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: A multicentre retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler"},{"key":"R68-2-20240830","doi-asserted-by":"crossref","first-page":"16727","DOI":"10.1038\/s41598-020-73882-8","article-title":"Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis","volume":"10","author":"Songwisit","year":"2020","journal-title":"Sci Rep"},{"key":"R69-2-20240830","doi-asserted-by":"crossref","first-page":"103181","DOI":"10.1016\/j.msard.2021.103181","article-title":"Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis","volume":"55","author":"Wang","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"R70-2-20240830","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: Multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"R71-2-20240830","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/1352458516678474","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders","volume":"23","author":"Montcuquet","year":"2017","journal-title":"Mult Scler"},{"key":"R72-2-20240830","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): A multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"R73-2-20240830","doi-asserted-by":"crossref","first-page":"103730","DOI":"10.1016\/j.msard.2022.103730","article-title":"Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration","volume":"60","author":"Tahara","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"R74-2-20240830","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2174\/18756190MTA2cMjAm1","article-title":"Anti-IL-6 therapies for neuromyelitis optica spectrum disorders: A systematic review of safety and efficacy","volume":"19","author":"Lotan","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"R75-2-20240830","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): An open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"key":"R76-2-20240830","doi-asserted-by":"crossref","first-page":"e1100","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R77-2-20240830","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Mol Immunol"},{"key":"R78-2-20240830","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuropharm.2018.02.002","article-title":"Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica","volume":"133","author":"Tradtrantip","year":"2018","journal-title":"Neuropharmacology"},{"key":"R79-2-20240830","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: An open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol"},{"key":"R80-2-20240830","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"R81-2-20240830","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): A double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"R82-2-20240830","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-020-01380-2","article-title":"Satralizumab: First Approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"R83-2-20240830","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1038\/nbt.1691","article-title":"Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization","volume":"28","author":"Igawa","year":"2010","journal-title":"Nat Biotechnol"},{"key":"R84-2-20240830","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: A randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"R85-2-20240830","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"R86-2-20240830","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-019-00742-8","article-title":"Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab","volume":"58","author":"Wijnsma","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"R87-2-20240830","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1038\/s41409-020-0810-z","article-title":"Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: A PRISMA-compliant meta-analysis","volume":"55","author":"Zhang","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R88-2-20240830","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1073\/pnas.1820039116","article-title":"Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial","volume":"116","author":"Zubizarreta","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R89-2-20240830","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/ana.21370","article-title":"Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis","volume":"63","author":"Garren","year":"2008","journal-title":"Ann Neurol"},{"key":"R90-2-20240830","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1212\/NXI.0000000000000277","article-title":"Restoring immune tolerance in neuromyelitis optica: Part II","volume":"3","author":"Bar-Or","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R91-2-20240830","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1212\/NXI.0000000000000276","article-title":"Restoring immune tolerance in neuromyelitis optica: Part I","volume":"3","author":"Steinman","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R92-2-20240830","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/25785826.2018.1531190","article-title":"Blood-brain barrier dysfunction in immuno-mediated neurological diseases","volume":"41","author":"Shimizu","year":"2018","journal-title":"Immunol Med"},{"key":"R93-2-20240830","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/14712598.2021.1884223","article-title":"Targeting the complement system in neuromyelitis optica spectrum disorder","volume":"21","author":"Asavapanumas","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"R94-2-20240830","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: State-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"R95-2-20240830","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1212\/NXI.0000000000000919","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2","volume":"8","author":"Graf","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R96-2-20240830","doi-asserted-by":"crossref","first-page":"e918","DOI":"10.1212\/NXI.0000000000000918","article-title":"Targeting B cells to modify MS, NMOSD, and MOGAD: Part 1","volume":"8","author":"Graf","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R97-2-20240830","doi-asserted-by":"crossref","first-page":"107827","DOI":"10.1016\/j.neuropharm.2019.107827","article-title":"Affinity-matured \u2018aquaporumab\u2019 anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders","volume":"162","author":"Duan","year":"2020","journal-title":"Neuropharmacology"},{"key":"R98-2-20240830","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann Neurol"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/2211-5056.355617","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:12:30Z","timestamp":1787757150000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2211-5056.355617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":97,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/2211-5056.355617","relation":{},"ISSN":["2211-5056"],"issn-type":[{"value":"2211-5056","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}